| Age (years), mean±SD |
60.1±15.1 |
58.8±15.7 |
60.3±15.1 |
0.56 |
| Male gender, N (%) |
233 (75.2) |
30 (73.2) |
203 (75.5) |
0.75 |
|
| Body mass index* (kg/m2), median (Q1, Q3) |
28.9 (25.0, 34.1) |
27.1 (24.4, 33.3) |
29.1 (25.1, 34.2) |
0.32 |
| No obesity < 30 kg/m2, N (%) |
169 (55.6) |
25 (62.5) |
144 (54.5) |
|
| Obesity 30-39.9 kg/m2, N (%) |
110 (36.2) |
10 (25.0) |
100 (37.9) |
0.22 |
| Obesity ≥ 40 kg/m2, N (%) |
25 (8.2) |
5 (12.5) |
20 (7.6) |
|
|
| Comorbid conditions, N (%) |
|
|
|
|
| Hypertension |
173 (56.0) |
22 (53.7) |
151 (56.3) |
0.75 |
| Diabetes |
173 (56.0) |
22 (53.7) |
151 (56.3) |
0.75 |
| Congestive heart failure |
22 (7.1) |
1 (2.4) |
21 (7.8) |
0.21 |
| COPD |
10 (3.2) |
0 (0) |
10 (3.7) |
0.21 |
| Bronchial asthma |
18 (5.8) |
6 (14.6) |
12 (4.5) |
0.02 |
| Chronic kidney disease |
36 (11.7) |
3 (7.3) |
33 (12.3) |
0.35 |
| Hemodialysis |
11 (3.6) |
11 (3.6) |
9 (3.4) |
0.63 |
| Previous VTE, N (%) |
11 (3.5) |
1 (2.4) |
10 (3.7) |
1.0 |
| History of thrombophilia |
9 (2.9) |
1 (2.4) |
8 (3.0) |
1.0 |
| Prior anticoagulation |
20 (6.5) |
2 (4.9) |
18 (6.7) |
1.0 |
| GCS on admission, mean±SD |
12.3±4.5 |
11.5±4.9 |
12.5±4.4 |
0.21 |
| SOFA on admission, mean±SD |
6.1±3.9 |
6.5±3.9 |
6.0±3.9 |
0.52 |
| SOFA at day 7, mean±SD |
6.8±4.3 |
7.2±3.6 |
6.7±4.4 |
0.45 |
|
| Pertinent laboratory findings on admission |
|
|
|
|
| Creatinine (μmol/L), median (Q1, Q3) |
93.0 (73.0, 144.5) |
103.0 (71.5, 139.5) |
93.0 (73.0, 146.8) |
0.97 |
| WBC x 109/L, median (Q1, Q3) |
9.82 (6.65, 13.80) |
10.80 (7.37, 16.10) |
9.81 (6.51, 13.75) |
0.22 |
| Neutrophils |
7.94 (4.95, 11.55) |
7.82 (5.45, 11.70) |
7.95 (4.88, 11.54) |
0.51 |
| Lymphocytes |
0.93 (0.63, 1.41) |
0.89 (0.62, 1.32) |
0.94 (0.64, 1.42) |
0.54 |
| Admission hemoglobin (g/L), mean±SD |
129±24 |
132±25 |
128±24 |
0.37 |
| Admission platelets x 109/L, mean±SD |
279±120 |
291±137 |
278±117 |
0.51 |
| PTT in seconds, median (Q1, Q3) |
29.1 (26.5, 32.6) |
28.5 (26.0, 32.8) |
29.3 (26.5, 32.6) |
0.61 |
| INR, median (Q1, Q3) |
1.10 (1.04, 1.18) |
1.12 (1.06, 1.30) |
1.10 (1.03, 1.18) |
0.12 |
| Lactate (mmol/L), mean±SD |
2.6±2.4 |
3.1±3.2 |
2.5±2.3 |
0.31 |
| Lactate dehydrogenase (U/L), median (Q1, Q3) |
553.0 (430.0, 749.0) |
615.0 (412.0, 837.0) |
544.5 (437.5, 731.5) |
0.23 |
| Fibrinogen (g/L), median (Q1, Q3) |
5.22 (3.81, 6.92) |
4.05 (2.62, 6.07) |
5.49 (3.97, 7.06) |
0.003 |
| D-Dimer (mg/L), median (Q1, Q3) |
1.70 (0.80, 4.05) |
3.86 (1.28, 14.43) |
1.47 (0.77, 3.72) |
0.001 |
| D-Dimer/fibrinogen ratio |
1.9±5.3 |
4.2±8.7 |
1.5±4.5 |
0.14 |
|
| Key interventions in the ICU before VTE |
|
|
|
|
| Central venous catheter |
206 (66.5) |
33 (80.5) |
173 (64.3) |
0.04 |
| Internal jugular |
156 (50.3) |
26 (63.4) |
130 (48.3) |
|
| Subclavian |
13 (4.2) |
3 (7.3) |
10 (3.7) |
0.20 |
| Femoral |
34 (11.0) |
4 (9.8) |
30 (11.2) |
|
| Vasopressor use, N (%) |
138 (44.7) |
27 (67.5) |
111 (41.3) |
0.002 |
| Invasive mechanical ventilation, N (%) |
208 (67.1) |
33 (80.5) |
175 (65.1) |
0.05 |
| PaO2/FiO2 ratio before intubation, median (Q1, Q3) |
92.5 (66.5, 164.3) |
90.0 (78.7, 214.5) |
95.8 (63.0, 153.0) |
0.17 |
| Renal replacement therapy, N (%) |
67 (21.6) |
11 (26.8) |
56 (20.8) |
0.38 |
